Home GU Oncology Now gu-oncology-now-picks

gu-oncology-now-picks

Immunotherapy Following Bladder Cancer Surgery May Reduce Recurrence, Study Finds

Predicting Immunotherapy Resistance in Bladder Cancer

Prostate Cancer Treatments: What’s Been Approved and What’s to Come

Enfortumab Vedotin as Third-Line Treatment Improves Overall Survival for Patients with Advanced Urothelial Carcinoma...

Lenvatinib plus Pembrolizumab Improves Overall Survival Compared to Sunitinib as First-Line Treatment for Advanced...

Adjuvant Nivolumab Improves Disease-Free Survival for Patients with Muscle-Invasive Urothelial Carcinoma in CheckMate 274

Cabozantinib Improves Progression-Free Survival over Sunitinib for Metastatic Papillary RCC in SWOG 1500

Circulating Tumor Cells Are Associated with Survival and Prognosis for Men Receiving Third-line Treatment...

177Lu-PSMA-617 Improves Progression-free Survival and Patient-reported Outcomes Compared to Cabazitaxel for Men with Metastatic...

Relugolix Effectively Suppresses Testosterone Levels Regardless of Other Simultaneous Prostate Cancer Treatments

Load more
Subscribe to RSS